An Acute Migraine Factorial Study

Phase 2

Completed

• Conditions: Migraine With or Without Aura
• Interventions: Drug: Naltrexone and Acetaminophen; Drug: Naltrexone Alone (regular dose); Drug: Matching Placebo; Drug: Naltrexone and Acetaminophen-High Dose; Drug: Acetaminophen Alone

• Registration Number: NCT06245902
• Lead Sponsor: Allodynic Therapeutics, Inc

Brief Summary

The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-18
• Primary Completion: 2018-02-08
• Study Completion: 2018-02-08
• Status Verified: 2024-01
• Study First Submitted: 2024-01-30
• Study First Submitted QC: 2024-01-30
• Last Update Submitted: 2024-01-30
• Study First Posted: 2024-02-07
• Last Update Posted: 2024-02-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 92

Inclusion Criteria

1. Male or female 18 years of age or older.
2. History of migraine with or without aura according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version) for at least one-year with first migraine prior to age 50.
3. Migraine-associated nausea with ≥half of migraine attacks.
4. 2 - 8 migraines per month in each of the previous 3 months.
5. The patient is able to complete study questionnaires, comply with the study requirements and restrictions, and willing to provide written informed consent and authorize HIPAA.
6. The female patient who is premenopausal or postmenopausal less than 1 year, or have not had surgical sterilization (i.e., tubal ligation, partial or complete hysterectomy) must have a negative urine pregnancy test, be non-lactating, and commit to using adequate and reliable contraception throughout the study (e.g., barrier with additional spermicidal, intra-uterine device, hormonal contraception). The male patient must be surgically sterile or commit to the use of 2 different methods of birth control during the study and for 28 days after taking the study drug.

Exclusion Criteria

1. The patient in the opinion of the investigator, may have medication-overuse headache pain (as defined by ICHD - 3 beta criteria for medication-overuse headache), (analgesic, opioid, ergotamine or triptan overuse) during the 3 months preceding screening.
2. The patient in the opinion of the investigator has chronic migraine (as defined by ICHD - 3 beta criteria for chronic migraine).
3. History of cluster headache or neurologically complicated migraine (hemiplegic, basilar, retinal, ophthalmoplegic migraine).
4. Initiation or change in medications with possible migraine prophylactic effects during 3 months before inclusion into the trial (E.g., calcium channel blockers, tricyclic antidepressants, beta-blockers, selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine re-uptake inhibitors (SNRIs), or Botox).
5. Any concurrent medical or psychiatric condition, this includes, but is not limited to chronic unstable debilitating diseases, significant renal or hepatic impairment.
6. A history within the previous 3 years of abuse of any drug, prescription, illicit, or alcohol.
7. The Female patient is pregnant or breast-feeding. The Male patient is not practicing 2 different methods of birth control with their partner during the study, and for 28 days after the investigational drug last dose or will not remain abstinent during the study, and for 28 days after the last dose.
8. Use of opiates or barbiturates more than 3 days per month.
9. Known-hypersensitivity reaction to any of the components of the investigational drug.
10. Consumption of analgesic medication for other conditions on a regular basis, (nonsteroidal anti-inflammatory drugs, or acetaminophen, or muscle relaxants).
11. Use of emergency care treatment more than 3 times in the previous 6 months.
12. Participation in another study with an investigational drug within 30 days prior to randomization and/or a plan to participate during the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Naltrexone and Acetaminophen	Naltrexone and Acetaminophen	Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
Naltrexone Alone Capsules	Naltrexone Alone (regular dose)	Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
Placebo Capsules	Matching Placebo	Patient take two capsule containing placebo together for a qualifying migraine
Naltrexon/Acetaminophen-High Capsules	Naltrexone and Acetaminophen-High Dose	Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
Acetaminophen Alone Capsules	Acetaminophen Alone	Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine

Primary Outcome Measures

Name	Time	Method
% of patients reporting no headache pain.	2 hours post-dose	Self-reported headache pain on a four-point Likert scale.
% of patients who have "sustained pain freedom"	24-hour post-dose.	Defined as having no headache pain at 2 hours after dose, with no use of rescue medication and no relapse of headache pain within 24 hours after administration of the investigational drug.
% of patients having absence of most bothersome migraine-associated symptom (MBS).	2 hours post-dose	MBS was prospectively identified at baseline. Self-reported MBS as present or absent.

Secondary Outcome Measures

Name	Time	Method
% of patients who used rescue medications	2-24 hours
% of patients who had headache pain relapse.	2-48 hours	Defined as the return of headache of any severity within 48 hours after administration of the investigational drug, when the patient was pain-free at 2 hours after the administration of the investigational drug.
% of patients having absence of nausea, photophobia, phonophobia, and neck/shoulder pain	24-hour post-dose.	Self-reported the current status of their associated symptom as present or absent.

Trial Locations

Locations (1)

Annette C. Toledano MD; 🇺🇸 North Miami, Florida, United States